CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 121 enrolled
Drug / intervention
WalkAide +2 moredevice
Likely dose
WalkAide neuromuscular stimulation system (6-week treatment phase in crossover arms)AI-extracted
Key inclusion· 8
  • Age ≥18 years
  • Stroke (CVA) diagnosed within the last 365 days
  • Inadequate dorsiflexion during swing phase of gait with inadequate limb clearance
  • Medically stable for ≥6 months prior to most recent stroke
Key exclusion· 13
  • Lower motor neuron injury with inadequate response to stimulation
  • History of falls >1 per week prior to CVA
  • Severe cardiac disease (MI, CHF, demand pacemaker, or other electrical stimulator)
  • Fixed ankle contractures ≥5° plantarflexion with knee extended

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00216320
NCT00216320N/ACompleted

A Three-Arm, Randomized Crossover Study Comparing the Innovative Neurotronics WalkAide™ System to Ankle-Foot Orthosis [AFO]

Innovative Neurotronics·interventional·Posted Sep 22, 2005·Updated Apr 19, 2013

In Brief

A clinical study evaluating WalkAide and AFO for Stroke. Completed, enrolled 121 participants across 5 sites.

Detailed Summary

To assess the effectiveness of a new stimulator (WalkAide) for the treatment of foot drop. The comparison will involve physical measurements (e.g. walking speed, physiological cost index, Modified Rivermead Mobility Index, etc.) and questionnaires on the quality of life and acceptance of the technology by stroke survivors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 22, 2005
Enrollment StartSep 1, 2005
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 20.8 years ago

Interventions

WalkAidedevice

Arm 1 - Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks

AFOdevice

Arm 2 - Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks

AFOdevice

Arm 3 - Subjects wear AFO for entire 12 weeks with no crossover